Fig. 4: The 11β-hydroxysteroid dehydrogenase type 1 inhibitor, AZD4017, prevents the rise in night-time diastolic blood pressure associated with 7 days of prednisolone + placebo treatment (A and B). | Nature Communications

Fig. 4: The 11β-hydroxysteroid dehydrogenase type 1 inhibitor, AZD4017, prevents the rise in night-time diastolic blood pressure associated with 7 days of prednisolone + placebo treatment (A and B).

From: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

Fig. 4: The 11β-hydroxysteroid dehydrogenase type 1 inhibitor, AZD4017, prevents the rise in night-time diastolic blood pressure associated with 7 days of prednisolone + placebo treatment (A and B).The alternative text for this image may have been generated using AI.

A Night-time diastolic blood pressure pre and post treatment in AZD4017+prednisolone and placebo+prednisolone groups. B Change in night-time diastolic blood pressure in AZD4017+prednisolone and placebo+prednisolone groups. Data are medians and error bars are IQR. Data points represent individual patients. AZD4017 + prednisolone; n = 13, placebo+prednisolone n = 14. (Light blue circles = pre-treatment AZD4017 + prednisolone, blue squares = post-treatment AZD4017 + prednisolone, pink circles = pre-treatment placebo+prednisolone, red squares = post-treatment placebo+prednisolone). Statistical tests: Wilcoxon signed-rank test; Fig. 4A, generalised linear models adjusting for baseline variability in each specified outcome; Fig. 4B.

Back to article page